KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biomarin Pharmaceutical (BMRN) Equity Income: 2009-2020

Historic Equity Income for Biomarin Pharmaceutical (BMRN) over the last 12 years, with Dec 2020 value amounting to -$6,000.

  • Biomarin Pharmaceutical's Equity Income rose 119.22% to $177,000 in Q3 2021 from the same period last year, while for Sep 2021 it was -$278,000, marking a year-over-year increase of 68.55%. This contributed to the annual value of -$6,000 for FY2020, which is 98.98% up from last year.
  • According to the latest figures from FY2020, Biomarin Pharmaceutical's Equity Income is -$6,000, which was up 98.98% from -$587,000 recorded in FY2019.
  • In the past 5 years, Biomarin Pharmaceutical's Equity Income registered a high of -$6,000 during FY2020, and its lowest value of -$1.3 million during FY2017.
  • Over the past 3 years, Biomarin Pharmaceutical's median Equity Income value was -$553,000 (recorded in 2018), while the average stood at -$382,000.
  • In the last 5 years, Biomarin Pharmaceutical's Equity Income slumped by 139.96% in 2017 and then skyrocketed by 98.98% in 2020.
  • Yearly analysis of 5 years shows Biomarin Pharmaceutical's Equity Income stood at -$538,000 in 2016, then slumped by 139.96% to -$1.3 million in 2017, then spiked by 57.16% to -$553,000 in 2018, then declined by 6.15% to -$587,000 in 2019, then skyrocketed by 98.98% to -$6,000 in 2020.